TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00865813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Biopsy
Description: 1. Instillation of anesthetic eye drops.~2. Asepsis~3. Placement of surgical cloths and drapes~4. Infiltration of the involved region with anesthetic solution plus adrenalin in1:200.00 dilution.~5. Trephination of the most typical area of the lesion with a punch (2mm in diameter) of stainless steel by applying gentle pressure and twisting the trephine until its introduction into the suspicious lesions~6. Removal of the excised tissue with the aid of an insulin needle or conjuntival forceps, the base then bein cut with an number 11 surgical blade
Study: NCT03462498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-months DAPT
Description: 1-month DAPT followed by 59-month monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12-month DAPT
Description: 12-month DAPT followed by 48-month monotherapy
Study: NCT01022164

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fibrin glue
Study: NCT02671825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR0200
Description: PUR0200 dry powder inhalation
Study: NCT01046422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Capsule, Oral, 15mg, Active, Daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Capsule, Oral, 50mg, Active, Daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Capsule, Oral, 150mg, Active, Daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Capsule, Oral, 50mg BID, Active, Daily, 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, 0mg, Daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
Study: NCT02110511

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: blended lentils
Description: blended lentils burritto breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blended lentils
Description: blended lentils burritto breakfast

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: whole lentils
Description: whole lentils breakfast burritto

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole lentils
Description: whole lentils breakfast burritto

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no lentils
Description: No lentils control breakfast burritto

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no lentils
Description: No lentils control breakfast burritto
Study: NCT04080063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted physical activity
Description: The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
Study: NCT01009138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes-Specific CBT (DS-CBT)
Description: 5 Group Sessions with a duration of 90 Minutes each, including the following cognitive-behavioral Intervention Methods focusing on Diabetes Distress and Hassles:~* Problem Analysis and Definition~* Problem Solving Intervention~* Cognitive Restructuring~* Activation of personal and social Resources~* Goal Definition and Agreement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Education
Description: Standard Diabetes Education Lesson including~* Health Care and specific Topics (e. g. Blood Pressure)~* Social Aspects of Living with Diabetes~* Diabetes Complications~* Sports, Activities and Exercise~* Healthy and unhealthy Food, Vitamins, Cooking Recommendations and Recipes~* Foot Care: Exercises, Care and Control, Sensibility, Injuries, diabetic Neuropathy
Study: NCT02974725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: LXH254 will be supplied as tablet for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: LXH254 will be supplied as tablet for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: LXH254 will be supplied as tablet for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: LTT462 will be supplied as hard gelatin capsule for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be supplied as film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib will be supplied in tablets and hard gelatin capsules.
Study: NCT01650935

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet
Description: When the first set of urine samples confirmed hyperoxaluria (urine oxalate\>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet
Description: When the first set of urine samples confirmed hyperoxaluria (urine oxalate\>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study
Study: NCT02205099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKL15508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKL15508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKL15508

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03536078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home phototherapy
Study: NCT02671825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR0200
Description: PUR0200 dry powder inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR0200
Description: PUR0200 dry powder inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR0200
Description: PUR0200 dry powder inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR0200
Description: PUR0200 dry powder inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: Dry Powder Inhalation Reference Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: Dry Powder Inhalation Reference Product
Study: NCT01711619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subcutaneous nerve stimulation
Description: subcutaneous nerve stimulation plus optimized medical management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Medical Management
Description: Optimized medical management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Medical Management
Description: Optimized medical management
Study: NCT00881907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Antibiotic Paste
Description: ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Antibiotic Paste
Description: ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Antibiotic Paste
Description: ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
Study: NCT00796744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NorLeu3-A(1-7) in a gel formulation
Description: Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NorLeu3-A(1-7) in a gel formulation
Description: Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NorLeu3-A(1-7) in a gel formulation
Description: Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
Study: NCT03104218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS group
Description: Interventions: movement training, strengthening, patient education. tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training).40 The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles)57, contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo group
Description: Interventions: movement training, strengthening, patient education. The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition.
Study: NCT04504175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine will be infused using an IV infusion pump at a rate of 0.5 mg/kg of body weight over 40 minutes
Study: NCT00659776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2\* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2\* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2\* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)
Study: NCT01759836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: Atorvastatin 20mg daily for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 20mg
Description: Atorvastatin 20mg daily for 1 year
Study: NCT01036659

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Description: subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Description: subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
Study: NCT03057964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDL (Pulsed Dye Laser)
Description: For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Photothermolysis Laser
Description: For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
Study: NCT03856333

Intervention type: OTHER
Group type: OTHER
Intervention: Assigned Interventions
Description: exercises, physical agents
Study: NCT01929954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gintuit
Description: One time placement of Gintuit over socket graft.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Gide
Description: One time placement of Bio-Gide over socket graft.
Study: NCT03280225

Intervention type: OTHER
Intervention: External facilitation
Description: Facilitation is an evidence-based implementation strategy to support sites that have difficulty implementing innovative programs. Facilitation is a multi-faceted process of interactive problem solving and support that occurs in the context of a recognized need for improvement and a supportive interpersonal relationship (Powell et al., 2015). Facilitation has been used nationally across VA to implement a number of different clinical interventions. The current project will examine this minimally intensive version of implementation facilitation, virtual external facilitation.
Study: NCT00791830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Tablets, 300 mg \* 1 daily, 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching irbesartan 150 mg
Description: Tablets, 300 mg \* 1 daily, 1 year
Study: NCT02816541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvis Retroverted
Description: Pilates-based therapeutic exercises with the pelvis retroverted - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvis in Neutral Position
Description: Pilates-based therapeutic exercises with the pelvis in neutral position - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Aerobic exercises (walking) performed on a treadmill.
Study: NCT04045899

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proseal LMA
Description: The Proseal Laryngeal Mask Airway (p-LMA) has a dual cuff modified to provide better sealing, and a drainage tube for gastric tube insertion. These features attribute in increasing the safety of the p-LMA when used with positive pressure ventilation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Q LMA
Description: Air-Q LMA has a self-pressurizing cuff which inflates to adequate pressure during positive pressure ventilation thus eliminating the adverse effects of cuff over inflation associated with the use of Supraglottic airway device with an inflatable cuff.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain LMA
Description: The AmbuAuraGain™ is a disposable, preformed second generation SAD, anatomically curved with integrated gastric access and intubation capability, taking patient safety and airway management efficiency to a new level.
Study: NCT01687387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2102 at 0.1 mg/kg
Description: every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2102 at 1 mg/kg
Description: every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (normal saline solution)
Description: every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline solution)
Description: every 4 weeks
Study: NCT02424864

Intervention type: OTHER
Group type: OTHER
Intervention: 4d PET-CT
Description: Patients will be imaged with 4D-CT images in addition to the normal protocol of FDG-CT image acquisition
Study: NCT02073318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented balance training
Description: 4 weeks individualized task-oriented balance training, twice a week and 1 hour each session
Study: NCT02511340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumatinib mesylate tablet 600 mg qd
Description: Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
Study: NCT01540903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline
Study: NCT04419649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050
Description: KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050
Description: KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050
Description: KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050
Description: KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050
Description: KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050
Description: KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
Study: NCT03820869

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family Training
Description: Family Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Occupational Therapy
Study: NCT03233347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV
Study: NCT02287740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance
Description: The protocol involves a core 8-form routine training with built-in variations and a subroutine of integrated therapeutic movements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Exercise
Description: The protocol involves a multi-modality program that involves aerobic, strength, balance, and flexibility exercises.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching
Description: The protocol represents a minimum standard of practice for exercises for older adults with activities consisting primarily of seated exercises accompanied by breathing, stretching, and relaxation.
Study: NCT00409409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IR grass pollen allergen extract tablet
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study: NCT02073318

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremities exercise
Description: 4 weeks upper extremities exercise in sitting position, twice a week and 1 hour each session~weeks